Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 4/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375895 | 1.00 | ADORA2A (0.55) | ADORA2AADORA1PTGS2PTGS1ESR2 | |
| SCHEMBL12326172 | 0.89 | PTGS2 (0.53) | ADORA2AADORA1PTGS2PTGS1KMT2A | |
| SCHEMBL9617394 | 0.86 | CYP17A1 (0.49) | ADORA2AADORA1PTGS2PTGS1KMT2A | |
| Chloroneb SCHEMBL4292226 | 0.85 | MAPK10 (0.51) | ADORA2AADORA1KMT2AMEN1L3MBTL1 | |
| SCHEMBL457121 | 0.84 | DYRK1A (0.56) | ESR2KMT2AMEN1L3MBTL1ACLY | |
| SCHEMBL12603887 | 0.84 | TAS1R3 (0.49) | PTGS2PTGS1ESR2ACLYALDH1A1 | |
| SCHEMBL13906293 | 0.84 | ACHE (0.54) | PTGS2PTGS1KMT2AMEN1L3MBTL1 | |
| SCHEMBL23909988 | 0.82 | ALDH1A1 (0.48) | ADORA2AADORA1PTGS2PTGS1KMT2A | |
| SCHEMBL13906296 | 0.82 | PTGS2 (0.50) | PTGS2PTGS1KMT2AACLYKMO | |
| SCHEMBL21116012 | 0.82 | ADORA2A (0.50) | ADORA2AADORA1PTGS2PTGS1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117623947-B | Synthesis method of bifenazate intermediate | 绍兴上虞新银邦生化有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12227485-B2 | Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni | INTERVET INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-12157717-B2 | Compounds for the treatment of bovine or swine respiratory disease | INTERVET INC. (US) | 2024-12-03 | — | — | US | disclosed |
| CN-117623947-A | Synthesis method of bifenazate intermediate | 绍兴上虞新银邦生化有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-116813507-A | Synthesis method of 5-substituent-2-alkoxy phenyl hydrazino formate compound | 绍兴上虞新银邦生化有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-110300578-B | Compounds for the treatment of respiratory diseases in cattle or pigs | 英特维特国际股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-11406617-B2 | Compounds for the treatment of bovine or swine respiratory disease | INTERVET INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220169581-A1 | DIRECT AROMATIC CARBON-OXYGEN AND CARBON-HYDROGEN BOND FUNCTIONALIZATION VIA ORGANIC PHOTOREDOX CATALYST | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2022-06-02 | — | — | US | disclosed |
| US-11202775-B2 | Methods for treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2021-12-21 | — | — | US | disclosed |
| WO-2004048365-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-05-06 | — | — | US | disclosed |
| WO-2003082272-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| CN-1208403-A | Compounds | BRITISH ASTRA PHARMACEUTICALS (GB) | 1999-02-17 | — | — | CN | disclosed |
| US-4431660-A | UROGENITAL DISORDERS; ENZYME INHIBITORS; KIDNEY AND BLADDER STONES | MERCK & CO., INC. (US) | 1984-02-14 | — | — | US | disclosed |
| EP-0021228-B1 | 4-SUBSTITUTED-3-HYDROXY-3-PYRROLINE-2,5-DIONE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | MERCK & CO. INC. (US) | 1982-09-01 | — | — | EP | disclosed |
| US-4256758-A | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase | MERCK & CO., INC. (US) | 1981-03-17 | — | — | US | disclosed |
| EP-0021228-A1 | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione compounds, process for their preparation and pharmaceutical compositions containing the same | MERCK & CO. INC. (US) | 1981-01-07 | — | — | EP | disclosed |
| US-4216109-A | BROAD TEMPERATURE AND CHEMICAL STABILITY; TIMEPIECES | CITIZEN WATCH CO., LTD. (JP) | 1980-08-05 | — | — | US | disclosed |
| US-4138359-A | CHLOROBIPHENYL BENZOATES, BROAD RANGE OF TEMPERATURE STABILITY, CHEMICAL RESISTANCE | CITIZEN WATCH CO., LTD. (JP) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | ADORA2A 4336/4885ADORA1 4219/4885PTGS2 3583/4885 |
| US-20220169581-A1 | DIRECT AROMATIC CARBON-OXYGEN AND CARBON-HYDROGEN BOND FUNCTIONALIZATION VIA ORGANIC PHOTOREDOX CATALYST | PPOX, CYCS, SCO2 | ADORA2A 950/4885ADORA1 1400/4885PTGS2 3377/4885 |
| US-11202775-B2 | Methods for treatment of cancer | TP53, TOP2B, BRCA1 | ADORA2A 2488/4885ADORA1 4177/4885PTGS2 2087/4885 |
| US-12227485-B2 | Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni | SORD, HEXD, SNRPD1 | ADORA2A 3040/4885ADORA1 3084/4885PTGS2 1037/4885 |
| US-11406617-B2 | Compounds for the treatment of bovine or swine respiratory disease | PIGS, BTD, PPARD | ADORA2A 1027/4885ADORA1 907/4885PTGS2 1409/4885 |
| US-12157717-B2 | Compounds for the treatment of bovine or swine respiratory disease | PIGS, BTD, PPARD | ADORA2A 1026/4885ADORA1 590/4885PTGS2 927/4885 |
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | TP53, TOP2B, BRCA1 | ADORA2A 2488/4885ADORA1 4177/4885PTGS2 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.